GlassScriptPhysician profile
Norman M Jacobowitz
NPI 1265746317
$54,688.26
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,193 · 2022: $3,790 · 2023: $14K · 2024: $22K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $13K · Food and Beverage: $6,437 · Honoraria: $5,750 · Travel and Lodging: $4,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,700.00 |
| Consulting Fee | $12,562.50 |
| Food and Beverage | $6,437.47 |
| Honoraria | $5,750.00 |
| Travel and Lodging | $4,255.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,682.86 | 2021-2025 | |
| Axsome Therapeutics, INC. | $23,332.01 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,407.91 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $599.08 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $505.12 | 2022-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $502.18 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $367.88 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $270.91 | 2021-2022 | |
| Corium, LLC | $239.74 | 2022-2025 | Azstarys, Adlarity |
| Ironshore Pharmaceuticals INC. | $176.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $150.70 | 2025 | Cobenfy |
| Alkermes, INC. | $142.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $89.31 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $65.21 | 2022-2025 | Spravato |
| Avanir Pharmaceuticals, INC. | $64.92 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.06 | 2023-2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.99 | 2024 | Abilify Maintena |
| Neos Therapeutics, LP | $21.07 | 2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $14.58 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Jacobowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.